Heparanase modulates heparinoids anticoagulant activities via non-enzymatic mechanisms

Summary

A key element for the physiological restriction of blood coagulation at the endothelial cell surface is its non-thrombogenic property, mainly attributed to cell surface heparan sulfate proteoglycans. Heparanase is an endo-β-D-glucuronidase with specific heparan sulfate degrading activity, which is produced and stored in platelets, and is released upon their activation. We examined the effects of heparanase pro-enzyme on coagulation functions, predominantly under physiological conditions. While heparanase pro-enzyme does not directly affect coagulation protein activities, it has profound effects on heparinoid-mediated regulation of coagulation responses, apparently via mechanisms that do not involve its enzymatic activity. Heparanase pro-enzyme reverses the anti-coagulant activity of unfractionated heparin on the coagulation pathway as well as on thrombin activity. In addition, heparanase pro-enzyme abrogated the factor X inhibitory activity of low-molecular-weight heparin (LMWH). The pro-coagulant effects of the non-active heparanase were also exerted by its major functional heparin-binding peptide. Finally, the effects of heparanase on the activity of factor VII activating protease that is auto-activated by heparinoids indicated a complete antagonistic action of heparanase in this system. Altogether, heparanase pro-coagulant activities that were also demonstrated in plasma samples from patients under LMWH treatment,point to a possible use of this molecule as antagonist for heparinoid treatment.

Keywords

Factor X - heparan sulfate - heparin antagonist - platelets - thrombin

• References

• 1 Jackson CM. Models for reaction mechanisms in haemostasis – contributions from the study of prothrombin activation. Thromb Haemost 2007; 98: 24-35.
• 2 Labarrere CA, Pitts D, Halbrook H. et al. Natural anticoagulant pathways in normal and transplanted human hearts. J Heart Lung Transplant 1992; 11: 342-347.
• 3 de Agostini AI, Watkins SC, Slayter HS. et al. Localization of anticoagulantly active heparan sulfate proteoglycans in vascular endothelium: antithrombin binding on cultured endothelial cells and perfused rat aorta. J Cell Biol 1990; 111: 1293-1304.
• 4 Girardin EP, Hajmohammadi S, Birmele B. et al. Synthesis of anticoagulantly active heparan sulfate proteoglycans by glomerular epithelial cells involves multiple 3-O-sulfotransferase isoforms and a limiting precursor pool. J Biol Chem 2005; 280: 38059-38070.
• 5 Sarafanov AG, Makogonenko EM, Pechik IV. et al. Cell surface heparan sulfate proteoglycans participate in factor VIII catabolism mediated by low density lipoprotein receptor-related protein. J Biol Chem 2001; 276: 11970-11979.
• 6 Ho G, Broze Jr GJ, Schwartz AL. Role of heparan sulfate proteoglycans in the uptake and degradation of tissue factor pathway inhibitor-coagulation factor Xa complexes. J Biol Chem 1997; 272: 16838-16844.
• 7 Iozzo RV. Basement membrane proteoglycans: from cellar to ceiling. Nat Rev Mol Cell Biol 2005; 6: 646-656.
• 8 Vlodavsky I, Goldshmidt O, Zcharia E. et al. Mammalian heparanase: involvement in cancer metastasis, angiogenesis and normal development. Semin Cancer Biol 2002; 12: 121-129.
• 9 Vlodavsky I, Abboud-Jarrous G, Elkin M. et al. The impact of heparanase and heparin on cancer metastasis and angiogenesis. Pathophysiol Haemost Thromb 2006; 35: 116-127.
• 10 Cohen E, Atzmon R, Vlodavsky I. et al. Heparanase processing by lysosomal / endosomal protein preparation. FEBS Lett 2005; 579: 2334-2338.
• 11 Abboud-Jarrous G, Rangini-Guetta Z, Aingorn H. et al. Site-directed mutagenesis, proteolytic cleavage, and activation of human proheparanase. J Biol Chem 2005; 280: 13568-13575.
• 12 Fairbanks MB, Mildner AM, Leone JW. et al. Processing of the human heparanase precursor and evidence that the active enzyme is a heterodimer. J Biol Chem 1999; 274: 29587-29590.
• 13 Hulett MD, Freeman C, Hamdorf BJ. et al. Cloning of mammalian heparanase, an important enzyme in tumor invasion and metastasis. Nat Med 1999; 5: 803-809.
• 14 Freeman C, Parish CR. Human platelet heparanase: purification, characterization and catalytic activity. Biochem J 1998; 330: 1341-1350.
• 15 Brill A, Elinav H, Varon D. Differential role of platelet granular mediators in angiogenesis. Cardiovasc Res 2004; 63: 226-235.
• 16 Myler HA, West JL. Heparanase and platelet factor- 4 induce smooth muscle cell proliferation and migration via bFGF release from the ECM. J Biochem 2002; 131: 913-922.
• 17 Nasser NJ, Sarig G, Brenner B. et al. Heparanase neutralizes the anticoagulation properties of heparin and low-molecular-weight heparin. J Thromb Haemost 2006; 4: 560-565.
• 18 Romisch J. Factor VII activating protease (FSAP): a novel protease in hemostasis. Biol Chem 2002; 383: 1119-1124.
• 19 Kannemeier C, Feussner A, Stohr HA. et al. Factor VII and single-chain plasminogen activator-activating protease: activation and autoactivation of the proenzyme. Eur J Biochem 2001; 268: 3789-3796.
• 20 Zetser A, Bashenko Y, Miao HQ. et al. Heparanase affects adhesive and tumorigenic potential of human glioma cells. Cancer Res 2003; 63: 7733-7741.
• 21 Levy-Adam F, Abboud-Jarrous G, Guerrini M. et al. Identification and characterization of heparin/heparan sulfate binding domains of the endoglycosidase heparanase. J Biol Chem 2005; 280: 20457-20466.
• 22 Du HY, Ji SL, Song HF. et al. The relationship between the structure of dermatan sulfate derivatives and their antithrombotic activities. Thromb Res 2007; 119: 377-384.
• 23 Taylor KR, Gallo RL. Glycosaminoglycans and their proteoglycans: host-associated molecular patterns for initiation and modulation of inflammation. FASEB J 2006; 20: 9-22.
• 24 Brandt JT, Stephens RE, Hinkle Jr. GH. Neutralization of thrombin by antithrombin III in the presence of cultured human fibroblasts. Thromb Res 1988; 51: 187-196.
• 25 Schoen P, Lindhout T, Franssen J. et al. Low molecular weight heparin-catalyzed inactivation of factor Xa and thrombin by antithrombin III--effect of platelet factor 4. Thromb Haemost 1991; 66: 435-441.
• 26 Yahalom J, Eldor A, Fuks Z. et al. Degradation of sulfated proteoglycans in the subendothelial extracellular matrix by human platelet heparitinase. J Clin Invest 1984; 74: 1842-1849.
• 27 Ihrcke NS, Parker W, Reissner KJ. et al. Regulation of platelet heparanase during inflammation: role of pH and proteinases. J Cell Physiol 1998; 175: 255-267.
• 28 Gong F, Jemth P, Escobar Galvis ML. et al. Processing of macromolecular heparin by heparanase. J Biol Chem 2003; 278: 35152-35158.
• 29 Haimovitz-Friedman A, Falcone DJ, Eldor A. et al. Activation of platelet heparitinase by tumor cell-derived factors. Blood 1991; 78: 789-796.
• 30 Nadav L, Eldor A, Yacoby-Zeevi O. et al. Activation, processing and trafficking of extracellular heparanase by primary human fibroblasts. J Cell Sci 2002; 115: 2179-2187.
• 31 Nakazawa F, Kannemeier C, Shibamiya A. et al. Extracellular RNA is a natural cofactor for the (auto-)activation of factor VII-activating protease (FSAP). Biochem J 2005; 385: 831-838.
• 32 Kannemeier C, Al-Fakhri N, Preissner KT. et al. Factor VII-activating protease (FSAP) inhibits growth factor-mediated cell proliferation and migration of vascular smooth muscle cells. FASEB J 2004; 18: 728-730.
• 33 Wong GC, Giugliano RP, Antman EM. Use of lowmolecular- weight heparins in the management of acute coronary artery syndromes and percutaneous coronary intervention. J Am Med Assoc 2003; 289: 331-342.
• 34 Massonnet-Castel S, Pelissier E, Bara L. et al. Partial reversal of low molecular weight heparin (PK 10169) anti-Xa activity by protamine sulfate: in vitro and in vivo study during cardiac surgery with extracorporeal circulation. Haemostasis 1986; 16: 139-146.
• 35 Kanbak M, Kahraman S, Celebioglu B. et al. Prophylactic administration of histamine 1 and/or histamine 2 receptor blockers in the prevention of heparinand protamine-related haemodynamic effects. Anaesth Intensive Care 1996; 24: 559-563.
• 36 Kimmel SE, Sekeres M, Berlin JA. et al. Mortality and adverse events after protamine administration in patients undergoing cardiopulmonary bypass. Anesth Analg 2002; 94: 1402-1408.
• 37 Rauova L, Zhai L, Kowalska MA. et al. Role of platelet surface PF4 antigenic complexes in heparin-induced thrombocytopenia pathogenesis: diagnostic and therapeutic implications. Blood 2006; 107: 2346-2353.
• 38 Stafford-Smith M, Lefrak EA, Qazi AG. et al. Efficacy and safety of heparinase I versus protamine in patients undergoing coronary artery bypass grafting with and without cardiopulmonary bypass. Anesthesiology 2005; 103: 229-240.
• 39 Lindahl U. Heparan sulfate-protein interactions – A concept for drug design?. Thromb Haemost 2007; 98: 109-115.